But DLBCL patients with co-expression of PD-L1 and p-AKT had poorer 3 years OS (P=0.018) and 5 years OS (P=0.007) compared to patients with both negative expression of PD-L1 and p-AKT (Table 3). The gene discussed is AKT1; the disease is diffuse large B-cell lymphoma.